Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Change in Receivables (2016 - 2025)

Celldex Therapeutics has reported Change in Receivables over the past 16 years, most recently at $1.9 million for Q4 2025.

  • Quarterly results put Change in Receivables at $1.9 million for Q4 2025, up 1366.45% from a year ago — trailing twelve months through Dec 2025 was $1.3 million (up 168.21% YoY), and the annual figure for FY2025 was $1.3 million, up 168.21%.
  • Change in Receivables for Q4 2025 was $1.9 million at Celldex Therapeutics, up from -$974000.0 in the prior quarter.
  • Over the last five years, Change in Receivables for CLDX hit a ceiling of $2.4 million in Q4 2023 and a floor of -$1.3 million in Q2 2021.
  • Median Change in Receivables over the past 5 years was $26000.0 (2021), compared with a mean of $14157.9.
  • Peak annual rise in Change in Receivables hit 1403.8% in 2023, while the deepest fall reached 719.18% in 2023.
  • Celldex Therapeutics' Change in Receivables stood at -$25000.0 in 2021, then surged by 732.0% to $158000.0 in 2022, then surged by 1403.8% to $2.4 million in 2023, then plummeted by 106.4% to -$152000.0 in 2024, then surged by 1366.45% to $1.9 million in 2025.
  • The last three reported values for Change in Receivables were $1.9 million (Q4 2025), -$974000.0 (Q2 2025), and $364000.0 (Q1 2025) per Business Quant data.